Cargando…
Evaluation of Pharmacokinetics, Safety, and Drug‐Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults
Intravenous (IV) edaravone is approved as an amyotrophic lateral sclerosis (ALS) treatment. Because IV administration places a burden on patients, development of orally administered ALS treatments is needed. Therefore, 2 phase 1 studies of oral formulations of edaravone in healthy subjects examined...
Autores principales: | Shimizu, Hidetoshi, Nishimura, Yukiko, Shiide, Yoichi, Matsuda, Hideaki, Akimoto, Makoto, Matsuda, Munetomo, Nakamaru, Yoshinobu, Kato, Yuichiro, Kondo, Kazuoki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518673/ https://www.ncbi.nlm.nih.gov/pubmed/33704925 http://dx.doi.org/10.1002/cpdd.925 |
Ejemplares similares
-
Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects
por: Shimizu, Hidetoshi, et al.
Publicado: (2021) -
Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study
por: Shimizu, Hidetoshi, et al.
Publicado: (2022) -
A Randomized, Single‐Blind, Placebo‐Controlled, 3‐Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects
por: Shimizu, Hidetoshi, et al.
Publicado: (2020) -
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients
por: Abe, Koji, et al.
Publicado: (2014) -
Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection
por: Cha, Sun Joo, et al.
Publicado: (2022)